

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

September 21, 2017

**Department of Natural Resources, 1101 Riverside Dr,
Lacharrette/Nightingale Rooms, Jefferson City, MO**

Committee Members Present

Conrad Balcer, D.O.
Patrick Bryant, Pharm D
Jennifer Kemp-Oestreich, Pharm D
Laura Kingsley, Pharm D
Morgan Sperry, Pharm D - * Non-voting member this meeting

Guest of Committee Member

Kayla Leeser, UMKC School of Pharmacy

Contractors in Attendance:

Janelle Sheen, Pharm D, Conduent
Joshua Moore, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Rick Pope, Pharm D, Magellan

Others Attending:

Christy Brandmeyer
Josephine Garcia-Ferrer, Actelion
Michael Lafond, Abbvie
Ashley Polce, Abbvie
Stacy Underwood, Abbvie
Rose Mullen, Alkermes
Evan Rushing, Alkermes
Joseph Ghobriel, AstraZeneca

Michelle Hessman, AstraZeneca
Michelle Hessman, AstraZeneca
Stephen Jones, AstraZeneca
Marty Jo Delphen, Abbvie
Camille Kerr, Amgen
Randy McGinley, Bayer
Aaron Shaw, Boehringer Ingelheim
Melissa Laurie, Bristol-Myers Squibb

Lisa Tootle, Bristol-Myers Squibb
Jessica Petrie, Dermax Center
Thomas Anderson, Daiichi-Sankyo
Britt Manning, Daiichi-Sankyo
Tomas Perkins, Daiichi-Sankyo
Arthur Wainwright, Daiichi-Sankyo
Donna Osterlund, Genzyme
Michele Puyear, Giliad

MO HealthNet Staff Present:

Stephen Calloway, R.Ph, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Jenna McTeer, RN, Clinical Management
Angela Wilson, Manager, Band I
Frances (Franki) Moseley, Administrative Office Support Assistant
Mitch Ruth, Fiscal Unit Manager
Elizabeth Short, Medicaid Specialist
Dr. Timothy Kling, MD, Assistant Medical Director
Lisa E. Smith, Medicaid Specialist

Others Attending:

Brian Strickland, Giliad	Jen Davis, Kite Pharma
David Hale, Home State Health	Jim Bauman, Pfizer
Brian Macomson, Johnson & Johnson	Phillip King, Pfizer
Justin Crum, Gilead	Mike Havler, Sunovan
Brian Macomson, Johnson & Johnson	Torey Batts, Teva Pharma
Kathy Usher, Lexicon	Randi Lewandowski, Teva Pharma
Steve Naert, Lilly	Heather Maruska, United Health Group
Michael Ferrari, Merck	Tom Brock, United Therapeutics
Berend Koops, Merck	Don Nopper, United Therapeutics
Claudia Douds, Missouri Care	Peter Rossmann, United Therapeutics
Kim Moore, MPA	Eric Gardner, Vertex Pharm
Julie Deveo, Novartis	Shirla Kreutzna, Vital RX
Lon Lowery, Novartis	Ashley Lytton, Wipro
Tom Peddicord, Novartis	Geri Roling, Wipro
Rick Kegler, Otsuka	

Welcome, Introductions and Opening Remarks	Dr. Conrad Balcer, Chair called the meeting to order. Patrick Bryant and Morgan Sperry introduced a student as a guest, Kayla Leeser, UMKC School of Pharmacy. Stephen Calloway introduced himself and started the introductions and opening remarks.
Minutes Approval	Minutes of the June 15, 2017 Drug PA meeting were reviewed and approved. Jennifer Kemp-Oestreich motioned and Laura Kingsley seconded the motion. (See Roll Call Vote)
Pharmacy Program/Budget Update	Stephen Calloway presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
DUR Report	Stephen Calloway stated all PDL Renewals from the June 2017 Drug PA Meeting were ratified at the July 2017 DUR Board Meeting.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included the PDL decisions to be implemented January 2018. Pending ratification, PDL decisions from September/October will be implemented January 2018. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf

<p>Follow-Up Decisions from June 15, 2017 Drug Prior Authorization Committee Meeting: Targeted Immune Modulators, Insulins: Rapid-Acting, AntiDiabetic Combinations</p>	<p>Stephen Calloway reviewed the changes to the PDL's that were re-evaluated. On the Targeted Immune Modulators PDL one preferred agent was changed to non-preferred. On the Insulins: Rapid-Acting PDL one preferred was kept. On the Antidiabetic Combinations PDL: Oral and Injectable, they accepted the criteria changes, but will need to discuss with the DUR Board.</p> <ul style="list-style-type: none"> • Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. • Public Hearing – Melissa Laurie from Bristol-Myers Squibb provided testimony on Orencia for the Targeted immune Modulators PDL. • Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
<p>New Business</p>	
<p>New Drug Review</p>	<p>Stephen Calloway reviewed the new drug products that were identified for the quarter April, May, and June 2017 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> • Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. • Public Hearing –Dr. Rose Mullen from Alkermes provided testimony on Aristada and Vivatral. Torey Batts from Teva Pharm, provided testimony on Austedo. Thomas Anderson from Daiichi Sankyo provided testimony on MorphaBond. • Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
<p>Clinical Edits</p>	
<p>Short-Acting Opioids Clinical Edits</p>	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
<p>Opiate Dependence Agents PDL (Approved Criteria)</p>	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – Tom Peddicord from Novartis provided testimony on Entresto. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
<p>Emflaza® Clinical Edit</p>	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
<p>Tymlos®/Forteo® Clinical Edit</p>	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Bidil® Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List (PDL)	
ACE Inhibitor Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
ACE Inhibitors/Calcium Channel Blocker Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No Comments Entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
ACE Inhibitors/Diuretic Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Angiotensin Receptor Blocker Agents (ARB's)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Angiotensin Receptor Blocker/Diuretic Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Angiotensin Receptor/Calcium Channel Blocker Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Anticoagulant Agents: Oral and Subcutaneous	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiplatelet Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – Joseph Ghobrial from AstraZeneca provided testimony on Brilinta. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta Adrenergic Blockers and Diuretic Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Calcium Channel Blocker Agents (Dehydropyridines)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Calcium Channel Blocker Agents (Non-Dehydropyridines)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Direct Renin Inhibitors and Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Hepatitis C Therapy: Direct-Acting Antiviral Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. Conrad Balcer wanted the references updated and Mr. Calloway stated he would make the changes. • Public Hearing – No Comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Homozygous Familial Hypercholesterolemia Products	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Lipotropic Agents: Niacin and Combination Preparations	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Proton Pump Inhibitor Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Pulmonary Hypertension Agents: Inhaled/Injectable	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – Josephine Garcia-Ferrer from Actelion provided testimony on Uptravi/Opsumit. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Pulmonary Hypertension Agents: Oral	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Sympatholytic Antihypertensive Agents	<ul style="list-style-type: none"> • Discussion – This is a new PDL class being recommended for implementation. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Triglyceride Lowering Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</p>

Conduent Update	<p>Luke Boehmer, Pharm D, presented the following items for review. Call Center Statistics for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids both Pre-Implementation of the last dosing reductions and Post-implementation of the last dosage reductions. Call Center Statistics for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids both Pre-Implementation of the last dosing reductions and Post-implementation of the last dosage reductions. The overall Claims trends for Opioids since 2009 and the trend of patients taking over the recommended max dose since 2009. Dr. Boehmer also presented the FFS Overdose Incidence Report year over year since 2013.</p>
Program Utilization: Top 25 Drugs Summary	<p>Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2nd, 3rd, & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.</p>
Call Center Statistics/ CyberAccess Reports	<p>A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess.</p>
Adjourn	<p>The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) Attendees were advised to check the <u>calendar of events</u> on the MHD website for meeting location changes over the next few months. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, December 14, 2017 at the James C. Kirkpatrick State Information Center, 600 W. Main St., Jefferson City, MO.</p>

Roll Call Votes September 21, 2107

<u>Member</u>	Minutes	Targeted Immune Modulators	Insulins	Anti-Diabetic Combinations	New Drug Review	Short Acting Opioids	Opiate Dependence Agents
Conrad Balcer, D.O.	Y	Y	Y		Y	Y	S
Pat Bryant, Pharm D	Y	M	M		S	Y	M
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M	S	S	Y	M	M	Y
Laura Kingsley, Pharm D	S	Y	Y	S	Y	S	Y

<u>Member</u>	Emflaza	Tymlos	Bidil	ACE Inhibitor Agents	ACE Inhibitors/Calcium Channel Blocker Combinations	ACE Inhibitors/Diuretic Combinations Agents	Angiotensin Receptor Blocker Agents (ARB's)
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	M	M	S	M	M	S	M
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	S	S	M	S	Y	M	Y
Laura Kingsley, Pharm D	Y	Y	Y	Y	S	Y	S

<u>Member</u>	Angiotensin Receptor Blocker/Diuretic Combination	Angiotensin Receptor/Calcium Channel Blocker Combinations Agents	Anticoagulant Agents: Oral and Subcutaneous	Antiplatelet Agents	Beta Adrenergic Blockers and Combinations	Calcium Channel Blocker Agents- (Dehydropyridines)	Calcium Channel Blocker Agents(Non-Dehydropyridines)
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	Y	Y	Y	M	M	M
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M	M	S	M	Y	Y	Y
Laura Kingsley, Pharm D	S	S	M	S	S	S	S

<u>Member</u>	Direct Renin Inhibitors and Combinations Agents	Hepatitis C Therapy: Direct-Acting Antiviral Agents	Homozygous Familial Hypercholesterolemia Products	Lipotropic Agents: Niacin and Combination Agents	Lipotropic Agents: Statins-(HMG Co-A Reductase Inhibitors)	Proton Pump Inhibitor Agents	Pulmonary Hypertension Agents: Inhaled/Injectable
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	M	M	M	S	M	Y	M
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	Y	Y	Y	Y	Y	M	Y
Laura Kingsley, Pharm D	S	S	S	M	S	S	S

<u>Member</u>	Pulmonary Hypertension Agents:Oral	Sympatholytic Antihypertensive Agents	Triglyceride Lowering Agents	Meeting Adjourned			
Conrad Balcer, D.O.	Y	Y	Y	Y			
Pat Bryant, Pharm D	Y	M	M	M			
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M	Y	Y	S			
Laura Kingsley, Pharm D	S	S	S	Y			

<u>Member</u>							
Conrad Balcer, D.O.							
Pat Bryant, Pharm D							
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D							
Laura Kingsley, Pharm D							